{"entity":{"id":"2006","kind":"year","name":"2006 in oncology","aka":["2006"],"tldr":"Everything OnCo dates to 2006: 147 entries, 42 landmarks, 33 papers listed on people's pages, 24 papers and 15 approvals. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"147 dated entries in OnCo fall in 2006: 42 landmarks, 33 papers listed on people's pages, 24 papers, 15 approvals, 9 companies founded, 6 technologies, 6 trials reported, 5 journals founded, 4 regulatory events and 3 laws and regulations.\n\nOf those, 3 to the day, 1 to the month and 143 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2005","2007"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2006,"events":[{"group":"approval","date":"2006","precision":"year","title":"Bevacizumab approved in US","note":"NSCLC; later ovarian, cervical, RCC, glioblastoma, HCC","from":"bevacizumab","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"Cetuximab approved in US","note":"Head and neck squamous cell carcinoma with radiation","from":"cetuximab","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"Clofarabine approved in EU","note":"Relapsed or refractory ALL in children after at least two prior regimens (Evoltra)","from":"clofarabine","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"Dasatinib approved in US","note":"CML and Ph+ ALL resistant or intolerant to imatinib","from":"dasatinib","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"Decitabine approved in US","note":"Myelodysplastic syndromes, all FAB subtypes and IPSS intermediate-1 to high risk","from":"decitabine","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"Gemcitabine approved in US","note":"Ovarian cancer with carboplatin","from":"gemcitabine","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"HPV quadrivalent vaccine (types 6, 11, 16 and 18) approved in EU","note":"Prevention of premalignant genital lesions, cervical cancer and genital warts from age 9 (Gardasil); anal lesions and cancer added later","from":"hpv-quadrivalent-vaccine","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"HPV quadrivalent vaccine (types 6, 11, 16 and 18) approved in US","note":"Prevention of cervical, vulvar and vaginal cancers and precancers and genital warts caused by HPV 6, 11, 16 and 18 in females 9 to 26 (males 2009; anal cancer 2010); superseded by...","from":"hpv-quadrivalent-vaccine","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"Human normal immunoglobulin (IVIg) approved in EU","note":"Replacement therapy in hypogammaglobulinaemia with recurrent bacterial infections in CLL (after failed antibiotic prophylaxis) and plateau-phase multiple myeloma (after failed pneu...","from":"human-normal-immunoglobulin","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"Lenalidomide approved in US","note":"Relapsed myeloma with dexamethasone","from":"lenalidomide","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"Panitumumab approved in US","note":"EGFR-expressing mCRC after chemotherapy (later RAS wild-type)","from":"panitumumab","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"Sunitinib approved in US","note":"Advanced RCC; GIST after imatinib","from":"sunitinib","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"Thalidomide approved in US","note":"Newly diagnosed multiple myeloma with dexamethasone","from":"thalidomide","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"Trastuzumab approved in US","note":"Adjuvant HER2+ breast cancer","from":"trastuzumab","refs":[]},{"group":"approval","date":"2006","precision":"year","title":"Vorinostat approved in US","note":"Cutaneous manifestations of CTCL with progressive, persistent or recurrent disease after two systemic therapies","from":"vorinostat","refs":[]},{"group":"company","date":"2006","precision":"year","title":"Eureka Therapeutics founded","note":"Emeryville, California","from":"eureka-therapeutics","refs":[]},{"group":"company","date":"2006","precision":"year","title":"Galena Biopharma founded","note":"Portland, OR","from":"galena-biopharma","refs":[]},{"group":"company","date":"2006","precision":"year","title":"Greenwich LifeSciences founded","note":"Stafford, Texas","from":"greenwich-lifesciences","refs":[]},{"group":"company","date":"2006","precision":"year","title":"IceCure Medical founded","note":"Caesarea","from":"icecure-medical","refs":[]},{"group":"company","date":"2006","precision":"year","title":"Michelson Diagnostics founded","note":"Maidstone, Kent","from":"michelson-diagnostics","refs":[]},{"group":"company","date":"2006","precision":"year","title":"Olema Pharmaceuticals founded","note":"San Francisco","from":"olema-pharmaceuticals","refs":[]},{"group":"company","date":"2006","precision":"year","title":"PregLem founded","note":"Geneva","from":"preglem","refs":[]},{"group":"company","date":"2006","precision":"year","title":"Sante Ventures founded","note":"Austin, TX","from":"sante-ventures","refs":[]},{"group":"company","date":"2006","precision":"year","title":"Sorrento Therapeutics founded","note":"San Diego, CA","from":"sorrento-therapeutics","refs":[]},{"group":"history","date":"2006","precision":"year","title":"A9961: 23.4 Gy craniospinal radiotherapy with cisplatin-based chemotherapy gives 81 percent five-year event-free survival","note":"Group 3 and group 4 medulloblastoma (non-WNT/non-SHH)","from":"medulloblastoma-group-3-4","refs":["cisplatin","vincristine","lomustine","cyclophosphamide"]},{"group":"history","date":"2006","precision":"year","title":"ASCO guideline requires fertility preservation discussion before cancer treatment","note":"Adolescent and young adult cancers (ages 15 to 39)","from":"aya-cancers","refs":["fertility-preservation"]},{"group":"history","date":"2006","precision":"year","title":"Brachyury identified as a chordoma marker","note":"Chordoma. Vujovic and colleagues show near-universal nuclear brachyury expression.","from":"chordoma","refs":[]},{"group":"history","date":"2006","precision":"year","title":"Carolina Breast Cancer Study: basal-like tumours in 39 percent of young African American women","note":"Triple-negative breast cancer (TNBC). Carey and colleagues, 496 cases; 16 percent in other women.","from":"tnbc","refs":["paper-carey-race-breast-cancer-subtypes-cbcs-jama-2006","paper-bauer-triple-negative-california-registry-cancer-2007","idea-tnbc-disparities-in-access-and-outcomes"]},{"group":"history","date":"2006","precision":"year","title":"Cetuximab + radiation improves survival (Bonner)","note":"Head and neck squamous cell carcinoma. First targeted agent in HNSCC.","from":"head-and-neck","refs":["egfr"]},{"group":"history","date":"2006","precision":"year","title":"Cetuximab + RT","note":"Head and neck squamous cell carcinoma","from":"head-and-neck","refs":[]},{"group":"history","date":"2006","precision":"year","title":"Cetuximab approved for head and neck cancer","note":"Recurrent or metastatic head and neck squamous cell carcinoma","from":"recurrent-metastatic-hnscc","refs":["cetuximab","bonner-cetuximab-rt"]},{"group":"history","date":"2006","precision":"year","title":"Cetuximab with radiotherapy (Bonner) includes hypopharyngeal tumours","note":"Hypopharyngeal cancer","from":"hypopharyngeal-cancer","refs":["bonner-cetuximab-rt"]},{"group":"history","date":"2006","precision":"year","title":"Cetuximab with radiotherapy improves survival (Bonner)","note":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","from":"hpv-negative-head-and-neck-cancer","refs":["bonner-cetuximab-rt"]},{"group":"history","date":"2006","precision":"year","title":"Chile guarantees preventive cholecystectomy for gallstones at ages 35 to 49","note":"Gallbladder cancer. The GES programme, the world's only national prophylactic cholecystectomy policy against gallbladder cancer; 284,139 notifications by 2024.","from":"gallbladder","refs":["prophylactic-cholecystectomy","paper-samaniego-chile-ges-programme-evaluation-rev-med-chile-2024"]},{"group":"history","date":"2006","precision":"year","title":"CIMP defined, and tied to BRAF","note":"Colorectal cancer. 195 methylation markers across 295 tumours: CIMP-positive tumours are a distinct subset encompassing almost all BRAF-mutant cancers (odds ratio 203), and are whe...","from":"colorectal","refs":["paper-weisenberger-cimp-braf-mlh1-colorectal-nat-genet-2006","braf"]},{"group":"history","date":"2006","precision":"year","title":"CSF1 translocation identified","note":"Tenosynovial giant cell tumour (TGCT). West and colleagues show a CSF1-expressing neoplastic minority recruits the macrophage majority (PNAS).","from":"tenosynovial-giant-cell-tumour","refs":[]},{"group":"history","date":"2006","precision":"year","title":"Curtin and Bastian: KIT alterations found in mucosal and acral melanoma","note":"Mucosal melanoma","from":"mucosal-melanoma","refs":["kit"]},{"group":"history","date":"2006","precision":"year","title":"Dasatinib and nilotinib approved for resistant disease, later first line","note":"Chronic myeloid leukaemia, chronic phase","from":"cml-chronic-phase","refs":["dasatinib","nilotinib"]},{"group":"history","date":"2006","precision":"year","title":"First dedicated inflammatory breast cancer clinic and research programme opens at MD Anderson","note":"Inflammatory breast cancer","from":"inflammatory-breast-cancer","refs":["massimo-cristofanilli","naoto-ueno"]},{"group":"history","date":"2006","precision":"year","title":"First HPV vaccine (Gardasil) approved","note":"Cervical cancer","from":"cervical","refs":["gardasil-9","hpv-vaccine"]},{"group":"history","date":"2006","precision":"year","title":"Gene-expression studies first separate a WNT subgroup of medulloblastoma","note":"WNT-activated medulloblastoma","from":"medulloblastoma-wnt","refs":[]},{"group":"history","date":"2006","precision":"year","title":"HPV vaccine approved","note":"Cervical cancer","from":"cervical","refs":["hpv-vaccine"]},{"group":"history","date":"2006","precision":"year","title":"HPV vaccine approved","note":"Vaginal cancer. Protects against the HPV types that cause most vaginal, cervical and vulvar cancers.","from":"vaginal","refs":["hpv-vaccine","gardasil-9"]},{"group":"history","date":"2006","precision":"year","title":"HPV vaccine approved with protection against vaginal precancer","note":"Vaginal squamous cell carcinoma (HPV-associated)","from":"vaginal-squamous-cell-carcinoma","refs":["hpv-vaccine","gardasil-9"]},{"group":"history","date":"2006","precision":"year","title":"Imatinib approved for unresectable, recurrent or metastatic disease","note":"Dermatofibrosarcoma protuberans","from":"dermatofibrosarcoma-protuberans","refs":["imatinib"]},{"group":"history","date":"2006","precision":"year","title":"Lenalidomide approved","note":"Multiple myeloma","from":"multiple-myeloma","refs":["lenalidomide"]},{"group":"history","date":"2006","precision":"year","title":"MAGIC: perioperative chemotherapy for GEJ adenocarcinoma","note":"Oesophageal cancer","from":"esophageal","refs":["cytotoxic-chemotherapy"]},{"group":"history","date":"2006","precision":"year","title":"MAGIC: perioperative chemotherapy improves survival (ECF)","note":"Gastric & gastro-oesophageal junction cancer","from":"gastric","refs":["cytotoxic-chemotherapy"]},{"group":"history","date":"2006","precision":"year","title":"MD Anderson defines borderline resectable disease by degrees of vessel contact","note":"Borderline resectable pancreatic ductal adenocarcinoma","from":"borderline-resectable-pdac","refs":["resectability"]},{"group":"history","date":"2006","precision":"year","title":"Median survival passes twelve months","note":"Lung cancer (all types). ECOG 4599 added bevacizumab to chemotherapy in 878 patients with non-squamous disease: 12.3 against 10.3 months, with a risk of increased treatment-related...","from":"lung-cancer","refs":["paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006"]},{"group":"history","date":"2006","precision":"year","title":"MERCURY: magnetic resonance imaging predicts the surgical margin","note":"Colorectal cancer. In 408 patients across 11 European units, high-resolution pelvic magnetic resonance imaging predicted a clear circumferential margin with 92 percent specificity...","from":"colorectal","refs":["mri","circumferential-resection-margin"]},{"group":"history","date":"2006","precision":"year","title":"NCCN adopts a definition of borderline resectable pancreatic cancer","note":"Pancreatic ductal adenocarcinoma. Vessel contact on CT starts to decide who has surgery first and who has treatment first; the definition was revised yearly until the 2017 internat...","from":"pancreatic","refs":["nccn-resectability-criteria-pancreatic","resectability"]},{"group":"history","date":"2006","precision":"year","title":"NCI and LIVESTRONG Progress Review Group defines AYA oncology as ages 15 to 39 and documents the survival gap","note":"Adolescent and young adult cancers (ages 15 to 39)","from":"aya-cancers","refs":["aya-oncology"]},{"group":"history","date":"2006","precision":"year","title":"Population analysis shows survival matched by stage is equal after breast conservation and mastectomy","note":"Paget disease of the nipple","from":"paget-disease-of-the-nipple","refs":["mastectomy"]},{"group":"history","date":"2006","precision":"year","title":"Quadrivalent HPV vaccine approved; later trials show protection against anal precancer","note":"Anal high-grade squamous intraepithelial lesions (precursor)","from":"anal-hsil-precursor","refs":["hpv-vaccine","gardasil-9"]},{"group":"history","date":"2006","precision":"year","title":"Randomised trial shows radiofrequency ablation equals resection for small tumours (Chen)","note":"Early hepatocellular carcinoma (BCLC 0 and A)","from":"hcc-early","refs":["radiofrequency-ablation"]},{"group":"history","date":"2006","precision":"year","title":"Reduced-dose CSI (23.4 Gy) safe for average risk with chemotherapy (CCG 9892/ACNS0331)","note":"Medulloblastoma","from":"medulloblastoma","refs":[]},{"group":"history","date":"2006","precision":"year","title":"RTOG 9402 and EORTC 26951 report: PCV lengthens progression-free but not yet overall survival","note":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","from":"oligodendroglioma","refs":["rtog-9402","eortc-26951"]},{"group":"history","date":"2006","precision":"year","title":"Second-generation TKIs","note":"Chronic myeloid leukaemia (CML). Dasatinib (2006) and nilotinib (2007) approved for resistance; later first line (DASISION, ENESTnd).","from":"cml","refs":["dasatinib","nilotinib"]},{"group":"history","date":"2006","precision":"year","title":"Sendai consensus guidelines for the management of IPMN and MCN","note":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","from":"ipmn-cystic-precursors","refs":["resectability"]},{"group":"history","date":"2006","precision":"year","title":"Sunitinib approved after imatinib failure","note":"Gastrointestinal stromal tumour (GIST)","from":"gist","refs":["sunitinib"]},{"group":"history","date":"2006","precision":"year","title":"Sunitinib approved after imatinib failure","note":"Imatinib-resistant GIST","from":"gist-imatinib-resistant","refs":["sunitinib"]},{"group":"history","date":"2006","precision":"year","title":"Sunitinib approved; replaces interferon","note":"Renal cell carcinoma","from":"rcc","refs":["sunitinib"]},{"group":"history","date":"2006","precision":"year","title":"Temozolomide responses in aggressive pituitary tumours reported","note":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","from":"pituitary-tumours","refs":["temozolomide"]},{"group":"history","date":"2006","precision":"year","title":"Thalidomide with melphalan-prednisone improves survival in older patients","note":"Newly diagnosed multiple myeloma, transplant-ineligible","from":"myeloma-transplant-ineligible","refs":["thalidomide"]},{"group":"history","date":"2006","precision":"year","title":"Vorinostat: first HDAC inhibitor approved for any cancer","note":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","from":"cutaneous-t-cell-lymphoma","refs":["vorinostat"]},{"group":"journal","date":"2006","precision":"year","title":"Current hematologic malignancy reports founded","note":"Springer","from":"current-hematologic-malignancy-reports","refs":[]},{"group":"journal","date":"2006","precision":"year","title":"Journal of Thoracic Oncology founded","note":"Elsevier","from":"journal-of-thoracic-oncology","refs":[]},{"group":"journal","date":"2006","precision":"year","title":"Radiation oncology founded","note":"BMC (Springer Nature)","from":"radiation-oncology","refs":[]},{"group":"journal","date":"2006","precision":"year","title":"Recent patents on anti-cancer drug discovery founded","note":"Bentham Science Publishers","from":"recent-patents-on-anti-cancer-drug-discovery","refs":[]},{"group":"journal","date":"2006","precision":"year","title":"Targeted oncology founded","note":"Springer Nature (Adis)","from":"targeted-oncology","refs":[]},{"group":"law","date":"2006","precision":"year","title":"Conditional marketing authorisation (EU)","note":"European Union, regulation.","from":"conditional-approval","refs":[]},{"group":"law","date":"2006","precision":"year","title":"Medicare coverage with evidence development","note":"United States, guidance.","from":"medicare-ced","refs":[]},{"group":"law","date":"2006","precision":"year","title":"Regulation (EC) No 1901/2006: EU paediatric medicines","note":"European Union, regulation.","from":"eu-paediatric-regulation","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting","note":"Ezzo JM, Richardson MA, Vickers A, et al. The Cochrane database of systematic reviews.","from":"paper-ezzo-cochrane-database-syst-rev","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Bao 2006: glioma stem cells resist radiotherapy by activating the DNA damage response","note":"Bao S, Wu Q, McLendon RE, et al. Nature.","from":"paper-bao-glioma-stem-cells-radioresistance-nature-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Cancer as an evolutionary and ecological process","note":"Merlo LM, Pepper JW, Reid BJ, et al. Nature Reviews Cancer.","from":"paper-merlo-nat-rev-cancer","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Carcinoma of the vagina: FIGO 26th Annual Report on the results of treatment in gynecological cancer","note":"Beller U, Benedet JL, Creasman WT, et al. International Journal of Gynecology & Obstetrics.","from":"paper-figo-annual-report-carcinoma-of-the-vagina-ijgo-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Chronic health conditions in adult survivors of childhood cancer","note":"Oeffinger KC, Mertens AC, Sklar CA, et al. New England Journal of Medicine.","from":"paper-oeffinger-n-engl-j-med","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer","note":"Weisenberger DJ, Siegmund KD, Campan M, et al. Nature Genetics.","from":"paper-weisenberger-cimp-braf-mlh1-colorectal-nat-genet-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized c...","note":"Sakamoto J, Morita S, Oba K, et al. Cancer immunology, immunotherapy.","from":"paper-sakamoto-cancer-immunol-immunother","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity","note":"Doronina SO, Mendelsohn BA, Bovee TD, et al. Bioconjugate chemistry.","from":"paper-doronina-bioconjug-chem","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"EORTC risk tables for recurrence and progression in Ta and T1 bladder cancer","note":"Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. European Urology.","from":"paper-sylvester-eortc-risk-tables-eur-urol-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","note":"Stummer W, Pichlmeier U, Meinel T, et al. The Lancet Oncology.","from":"paper-stummer-lancet-oncol","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Galon 2006: the type, density and location of immune cells in colorectal tumours predict outcome","note":"Galon J, Costes A, Sanchez-Cabo F, et al. Science.","from":"paper-galon-immune-contexture-colorectal-science-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies","note":"Huang XJ, Liu DH, Liu KY, et al. Bone marrow transplantation.","from":"paper-huang-bone-marrow-transplant","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a r...","note":"Brune M, Castaigne S, Catalano J, et al. Blood.","from":"paper-study-0201-blood-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"MicroRNA signatures in human cancers","note":"Calin GA, Croce CM. Nature Reviews Cancer.","from":"paper-calin-nat-rev-cancer","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","note":"Sandler A, Gray R, Perry MC, et al. New England Journal of Medicine.","from":"paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Preneoplastic lesions in gallbladder cancer","note":"Roa I, de Aretxabala X, Araya JC, Roa J. Journal of Surgical Oncology.","from":"paper-roa-gallbladder-preneoplastic-lesions-jso-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","note":"Carey LA, Perou CM, Livasy CA, et al. JAMA.","from":"paper-carey-race-breast-cancer-subtypes-cbcs-jama-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Radiotherapy plus cetuximab for locoregionally advanced squamous cell carcinoma of the head and neck","note":"Bonner JA, Harari PM, Giralt J, et al. New England Journal of Medicine.","from":"paper-bonner-cetuximab-radiotherapy-nejm-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Semisynthetic maytansine analogues for the targeted treatment of cancer","note":"Widdison WC, Wilhelm SD, Cavanagh EE, et al. Journal of medicinal chemistry.","from":"paper-widdison-j-med-chem","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Somatic activation of KIT in distinct subtypes of melanoma","note":"Curtin JA, Busam K, Pinkel D, et al. Journal of Clinical Oncology.","from":"paper-curtin-kit-melanoma-jco-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Sunitinib in advanced gastrointestinal stromal tumour after failure of imatinib","note":"Demetri GD, van Oosterom AT, Garrett CR, et al. The Lancet.","from":"paper-demetri-sunitinib-gist-lancet-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"Systemic therapy in the palliative management of advanced salivary gland cancers (review)","note":"Laurie SA, Licitra L. Journal of Clinical Oncology.","from":"paper-laurie-licitra-salivary-systemic-jco-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"The epigenetic progenitor origin of human cancer","note":"Feinberg AP, Ohlsson R, Henikoff S. Nature reviews. Genetics.","from":"paper-feinberg-nat-rev-genet-2006","refs":[]},{"group":"paper","date":"2006","precision":"year","title":"The management of respiratory motion in radiation oncology report of AAPM Task Group 76","note":"Keall PJ, Mageras GS, Balter JM, et al. Medical physics.","from":"paper-keall-med-phys","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Activation of Mitogen-Activated Protein Kinase in Estrogen Receptor α–Positive Breast Cancer Cells In vitro Induces an In vivo Molecular Phenotype of Estrogen R...","note":"Cancer Research","from":"dorraya-el-ashry","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Airflow limitation and airway dimensions in chronic obstructive pulmonary disease","note":"American Journal of Respiratory and Critical Care Medicine","from":"yasuyuki-nasuhara","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Brief posturographic test as an indicator of fatigue","note":"Psychiatry Clin Neurosci","from":"erez-barenboim","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","note":"Science","from":"steven-rosenberg","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","note":"Journal of Experimental Medicine","from":"jeffrey-bluestone","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-...","note":"Blood","from":"michael-von-bergwelt","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Comparison of a single indicator and gravimetric technique for estimation of extravascular lung water in endotoxemic pigs","note":"Critical Care Medicine","from":"patrik-rossi","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Diagnostic architectural and dynamic features at breast MR imaging: multicenter study","note":"Radiology","from":"mitchell-schnall","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis","note":"The Lancet Oncology","from":"dan-theodorescu","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Effect of an extended scope physiotherapy service on patient satisfaction and the outcome of soft tissue injuries in an adult emergency department","note":"Emergency Medicine Journal","from":"jonathan-benger","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","note":"Lancet","from":"george-demetri","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Estrategias para un control eficaz de la hipertensión arterial en España. Documento de consenso","note":"Revista Española de Geriatría y Gerontología","from":"alvaro-bonet-pla","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","note":"JCO","from":"robert-timmerman","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and br...","note":"J Clin Oncol","from":"oddbjorn-straume","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia","note":"New England Journal of Medicine","from":"brian-druker","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Frontal Sinus Fractures: A Treatment Algorithm and Assessment of Outcomes Based on 78 Clinical Cases","note":"Plastic & Reconstructive Surgery","from":"chen-chien-tzung","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Global variation in copy number in the human genome","note":"Nature","from":"stephen-scherer","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer","note":"Cancer Res","from":"krisztina-bogos","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach","note":"Cell","from":"lars-zender","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Inhibition of Phosphatidylinositol 3-Kinase Destabilizes Mycn Protein and Blocks Malignant Progression in Neuroblastoma","note":"Cancer Research","from":"louis-chesler","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Is Base Excision Repair a Tumor Suppressor Mechanism?","note":"Cell Cycle","from":"joann-sweasy","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Key stages in mammary gland development - The alveolar switch: coordinating the proliferative cues and cell fate decisions that drive the formation of lobuloalv...","note":"Breast Cancer Research","from":"samantha-oakes","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Large Granular Lymphocyte Leukemia","note":"The Oncologist","from":"thomas-loughran","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis","note":"European Journal of Cancer","from":"vasanta-nanduri","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Molecular imaging in the development of cancer therapeutics","note":"Annual Review of Medicine","from":"johannes-czernin","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer (MAGIC)","note":"NEJM","from":"david-cunningham","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate canc...","note":"Journal of Clinical Oncology","from":"eric-small","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Platensimycin is a selective FabF inhibitor with potent antibiotic properties","note":"Nature","from":"fernando-pelaez","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medullo...","note":"Lancet Oncology","from":"amar-gajjar","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells","note":"Cancer Lett","from":"vasyl-f-chekhun","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Salivary gland neoplasms in children: The experience of the Istituto Nazionale Tumori of Milan","note":"Pediatric Blood & Cancer","from":"marco-guzzo","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Temporal and biological trends in liver cancers at a University hospital in Southwest Nigeria","note":"Tropical Doctor","from":"jesse-otegbayo","refs":[]},{"group":"person-paper","date":"2006","precision":"year","title":"Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer","note":"Journal of Clinical Oncology","from":"lori-pierce","refs":[]},{"group":"technology","date":"2006","precision":"year","title":"Biosimilar manufacturing and comparability","note":"First use in humans or first approval, as the technology record states it.","from":"biosimilar-manufacturing","refs":[]},{"group":"technology","date":"2006","precision":"year","title":"Dual-energy and spectral CT","note":"First use in humans or first approval, as the technology record states it.","from":"dual-energy-spectral-ct","refs":[]},{"group":"technology","date":"2006","precision":"year","title":"Electrochemotherapy devices (Cliniporator)","note":"First use in humans or first approval, as the technology record states it.","from":"electrochemotherapy-devices","refs":[]},{"group":"technology","date":"2006","precision":"year","title":"Evidence-based integrative oncology","note":"First use in humans or first approval, as the technology record states it.","from":"integrative-oncology","refs":[]},{"group":"technology","date":"2006","precision":"year","title":"Oncofertility and fertility preservation","note":"First use in humans or first approval, as the technology record states it.","from":"fertility-preservation","refs":[]},{"group":"technology","date":"2006","precision":"year","title":"Survivorship care and late-effects surveillance","note":"First use in humans or first approval, as the technology record states it.","from":"survivorship-care-plan","refs":[]},{"group":"trial","date":"2006","precision":"year","title":"ALMANAC (Axillary Lymphatic Mapping Against Nodal Axillary Clearance) reported","note":"At twelve months, lymphoedema 5 against 13 percent (relative risk 0.37) and sensory loss 11 against 31 percent (relative risk 0.37) after sentinel node biopsy against standard axil...","from":"almanac","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2006","precision":"year","title":"ANITA (Adjuvant Navelbine International Trialist Association) reported","note":"Median survival 65.7 against 43.7 months (hazard ratio 0.80); five-year overall survival improved by 8.6 percent.","from":"anita","refs":["resectable-nsclc","vinorelbine","cisplatin"]},{"group":"trial","date":"2006","precision":"year","title":"Bonner trial (cetuximab plus radiotherapy) reported","note":"Median overall survival 49.0 vs 29.3 months (hazard ratio 0.74).","from":"bonner-cetuximab-rt","refs":["head-and-neck","oropharyngeal-cancer","laryngeal-cancer","hypopharyngeal-cancer"]},{"group":"trial","date":"2006","precision":"year","title":"JROSG 99-1 (Aoyama): stereotactic radiosurgery with or without whole-brain radiotherapy reported","note":"Median survival 7.5 against 8.0 months (p=0.42); twelve-month brain recurrence 46.8 percent with whole-brain radiotherapy against 76.4 percent without.","from":"jrosg-99-1","refs":["nsclc","sclc","lung-cancer","secondary-brain-tumours"]},{"group":"trial","date":"2006","precision":"year","title":"MERCURY reported","note":"Magnetic resonance imaging predicted a clear circumferential resection margin correctly in 327 of 349 patients (94 percent), with 92 percent specificity, reproducibly across 11 uni...","from":"mercury","refs":["colorectal","rectal-cancer"]},{"group":"trial","date":"2006","precision":"year","title":"Study 0201 reported","note":"Leukaemia-free survival improved over observation in the full population (n=320, P<.01); in first complete remission, 3-year leukaemia-free survival 40% with histamine plus interle...","from":"study-0201","refs":["aml","histamine-dihydrochloride","aldesleukin"]},{"group":"regulatory","date":"2006-06-08","precision":"day","title":"Nonavalent HPV vaccine: approval (US)","note":"Original quadrivalent Gardasil approved","from":"gardasil-9","refs":[]},{"group":"regulatory","date":"2006-06-29","precision":"day","title":"Lenalidomide: approval (US)","note":"Myeloma with dexamethasone","from":"lenalidomide","refs":[]},{"group":"regulatory","date":"2006-09","precision":"month","title":"Panitumumab: approval (US)","note":"Accelerated approval, refractory mCRC","from":"panitumumab","refs":[]},{"group":"regulatory","date":"2006-11-16","precision":"day","title":"Trastuzumab: approval (US)","note":"Adjuvant HER2+ early breast cancer (HERA, NSABP B-31/N9831)","from":"trastuzumab","refs":[]}]},"route":"/years/2006/","neighbours":{"year":[{"id":"2005","kind":"year","name":"2005 in oncology","route":"/years/2005/"},{"id":"2007","kind":"year","name":"2007 in oncology","route":"/years/2007/"}]}}